DNA介导的细胞膜工程化修饰的研究进展

doi:10.16352/j.issn.1001-6325.2026.06.0872

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (6): 872-876.doi: 10.16352/j.issn.1001-6325.2026.06.0872

DNA介导的细胞膜工程化修饰的研究进展

张屹¹, 廖米琦², 郎明非^1*

1.大连大学基础医学院,辽宁大连 116622;
2.大连大学中山临床学院,辽宁大连 116622

收稿日期:2026-03-17 修回日期:2026-04-10 出版日期:2026-06-05 发布日期:2026-05-27
通讯作者: ^*langmingfei@dlu.edu.cn

Advances in DNA-mediated cell membrane engineering

ZHANG Yi¹, LIAO Miqi², LANG Mingfei^1*

1. School of Basic Medical Sciences;
2. Zhongshan Clinical College, Dalian University, Dalian 116622, China

Received:2026-03-17 Revised:2026-04-10 Online:2026-06-05 Published:2026-05-27
Contact: ^*langmingfei@dlu.edu.cn

摘要/Abstract

摘要： 细胞膜工程化修饰是赋予细胞新表型识别、响应与调控功能的关键技术,对细胞治疗与精准医学发展具有重要价值。DNA 纳米技术凭借优异的可编程性、可寻址性与生物相容性,在细胞膜精准功能化修饰中展现出独特优势。本文系统综述了基于寡核苷酸的细胞表面工程化最新研究进展,重点围绕化学共价修饰与非共价结合两大策略,系统阐述各类方法的修饰原理、技术特点及其在细胞治疗中的应用现状。最后,总结了 DNA 介导细胞表面修饰的主流策略,并对其在细胞工程与精准医学领域的发展前景进行展望。

关键词: 寡核苷酸, 细胞表面修饰, DNA纳米技术, 精准医学

Abstract: Cell membrane engineering is a key technology for endowing cells with novel recognition, response, and regulatory functions, which holds significant value for the advancement of cell therapy and precision medicine. DNA nanotechnology exhibits unique advantages in the precise functionalization of cell membranes owing to its excellent programmability, addressability, and biocompatibility. This article reviews the latest advances in cell membrane engineering based on oligonucleotides, focusing on two major strategies: chemical covalent modification and noncovalent binding. The modification mechanisms, technical characteristics, and application status of these methods in cell therapy are systematically elaborated. Finally, representative strategies for DNA-mediated cell membrane modification are summarized, and the development prospects in the fields of cell engineering and precision medicine are discussed.

Key words: oligonucleotides, cell surface modification, DNA nanotechnology, precision medicine

中图分类号:

R318.08

张屹, 廖米琦, 郎明非. DNA介导的细胞膜工程化修饰的研究进展[J]. 基础医学与临床, 2026, 46(6): 872-876.

ZHANG Yi¹, LIAO Miqi², LANG Mingfei^1*. Advances in DNA-mediated cell membrane engineering[J]. Basic & Clinical Medicine, 2026, 46(6): 872-876.

参考文献 24

[1]	惠利健, 袁湘, 吴婧琪. 细胞治疗药物:进展与展望[J]. 中国科学院院刊, 2024, 39: 1434-1446.
[2]	施明, 谢云波, 王福生. 肿瘤免疫细胞治疗:前景与挑战[J]. 中国肿瘤生物治疗杂志, 2024, 31: 1-9.
[3]	Fury B, Bauer G. GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and path-ways forward[J]. Mol Ther, 2025, 33: 1886-1888.
[4]	Chen Y, Tian R, Zhang Y, et al. Self-assembled DNA nanodevices for intelligent biosensing[J]. Nanoscale Horiz, 2026, 11: 114-132.
[5]	Dey S, Fan C, Gothelf KV, et al. DNA origami[J]. Nat Rev Methods Primers, 2021, 1. doi: 10.1038/s43586-020-00009-8.
[6]	Deng J, Zhang R, Qi H, et al. DNA technology-based cell membrane engineering for biomedical applications[J]. ACS Appl Bio Mater, 2025, 9: 686-706.
[7]	Hsiao S C, Shum B J, Onoe H, et al. Direct cell surface modification with DNA for the capture of primary cells and the investigation of myotube formation on defined patterns[J]. Langmuir, 2009, 25: 6985-6991.
[8]	Zhao W, Schafer S, Choi J, et al. Cell-surface sensors for real-time probing of cellular environments[J]. Nat Nanotechnol, 2011, 6: 524-531.
[9]	Ge Z, Liu J, Guo L, et al. Programming cell-cell communications with engineered cell origami clusters[J]. J Am Chem Soc, 2020, 142: 8800-8808.
[10]	Mahal LK, Yarema KJ, Bertozzi CR. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis[J]. Science, 1997, 276: 1125-1128.
[11]	Shi P, Zhao N, Lai J, et al. Polyvalent display of biomolecules on live cells[J]. Angew Chem Int Ed Engl, 2018, 57: 6800-6804.
[12]	Tang H, Xiong Y, Gan S, et al. CD4 aptamer-engineered cell platforms enhance anti-tumor immunity in triple-negative breast cancer[J]. Cell Biomater, 2026, 2. doi: 10.1016/j.celbio.2025.100218.
[13]	Liu X, Ye T, Yang L, et al. DNA-scaffolded bispecific antibodies enhance mesenchymal stromal cell therapy for inflammatory bowel disease[J]. Adv Mater, 2025, 38: e11854. doi: 10.1002/adma.202511854.
[14]	Wang X, Wang Y, Lee K, et al. Display of polyvalent hybrid antibodies on the cell surface for enhanced cell recognition[J]. Small Methods, 2023, 8: e2301331. doi: 10.1002/smtd.202301331.
[15]	Wang X, Jia B, Lee K, et al. Biomimetic bacterial capsule for enhanced aptamer display and cell recognition[J]. J Am Chem Soc, 2023, 146: 868-877.
[16]	Ye T, Liu X, Zhong X, et al. Nongenetic surface engineering of mesenchymal stromal cells with polyvalent antibodies to enhance targeting efficiency[J]. Nat Commun, 2023, 14: 5806. doi: 10.1038/s41467-023-41609-8.
[17]	Wang Y, Tian R, Li Z, et al. Mesenchymal stem cells engineered by multicomponent coassembled dna nanofibers for enhanced wound healing[J]. Nano Lett, 2024, 24: 13955-13964.
[18]	Xiong M, Kong G, Liu Q, et al. DNA-templated anchoring of proteins for programmable cell functionaliza-tion and immunological response[J]. Nano Lett, 2022, 23: 183-191.
[19]	Bagheri Y, Chedid S, Shafiei F, et al. A quantitative assessment of the dynamic modification of lipid-DNA probes on live cell membranes[J]. Chem Sci, 2019, 10: 11030-11040.
[20]	Hu KH, Eichorst JP, Mcginnis CS, et al. ZipSeq: barcoding for real-time mapping of single cell transcriptomes[J]. Nat Methods, 2020, 17: 833-843.
[21]	Zhang Z, Eckert MA, Ali MM, et al. DNA-scaffolded multivalent ligands to modulate cell function[J]. Chembiochem, 2014, 15: 1268-1273.
[22]	Li H, Wang M, Shi T, et al. A DNA-mediated chemically induced dimerization (D-CID) nanodevice for nongenetic receptor engineering to control cell behavior[J]. Angew Chem Int Ed Engl, 2018, 57: 10226-10230.
[23]	Javid H, Oryani MA, Rezagholinejad N, et al. RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions[J]. Cancer Med, 2024, 13: e6800. doi: 10.1002/cam4.6800.
[24]	Brockman JM, Su H, Blanchard AT, et al. Live-cell super-resolved PAINT imaging of piconewton cellular traction forces[J]. Nat Methods, 2020, 17: 1018-1024.

DNA介导的细胞膜工程化修饰的研究进展

Advances in DNA-mediated cell membrane engineering

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 14

编辑推荐

Metrics

本文评价

[1]	常佳慧, 任鹏举, 周赟懿, 蒋澄宇, 张艳丽. HJT-sRNA-m7本草体控制硅肺模型小鼠的纤维化进程[J]. 基础医学与临床, 2025, 45(7): 874-881.
[2]	李晓光, 杨璐, 刘旭东, 贾鑫淼, 杨欣壮, 崔丽英. 基因治疗肌萎缩侧索硬化机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 674-679.
[3]	刘雅萍, 张学. 精准医学时代下医学遗传学教学的新思路[J]. 基础医学与临床, 2020, 40(9): 1310-1312.
[4]	田发明张柳孟亚强张英泽. 辛伐他汀促进大鼠BMSCs分化为成骨细胞[J]. 基础医学与临床, 2010, 30(8): 820-825.
[5]	刘超侠孔庆兖*. 大蒜素联合生存素反义寡核苷酸对胃癌SGC7901细胞生长的影响[J]. 基础医学与临床, 2010, 30(11): 1197-1201.
[6]	周云松温晓辉杨林西陈朋. 骨桥蛋白反义核酸抑制乳腺癌细胞系增殖和诱导其凋亡[J]. 基础医学与临床, 2009, 29(8): 850-854.
[7]	周慷兰箭. Livin反义寡核苷酸对人HL60细胞增殖和凋亡的影响[J]. 基础医学与临床, 2009, 29(5): 527-530.
[8]	李尊岭邵淑红谢书阳焦飞石寿森于雪艳. CT120反义寡核苷酸抑制肺腺癌细胞A549的生长[J]. 基础医学与临床, 2009, 29(4): 400-404.
[9]	张扬蔺勇王晓军吉日嘎拉哈申高娃. MMP-28反义寡核苷酸对肺癌细胞生物学行为的影响[J]. 基础医学与临床, 2009, 29(10): 1026-1030.
[10]	黄红亮向军俭唐勇王宏邓宁靳英杰. 硫代bFGF寡核苷酸抑制HepG2和Hep2细胞的增殖[J]. 基础医学与临床, 2008, 28(3): 217-221.
[11]	陈玲胡建新程晓曙苏海洪葵李菊香吴延庆. 血小板反应蛋白1反义寡核苷酸抑制TGF-β1诱导大鼠心肌纤维化[J]. 基础医学与临床, 2008, 28(12): 1297-1299.
[12]	王岩. SELEX技术及其在医学中的应用[J]. 基础医学与临床, 2007, 27(7): 834-840.
[13]	刘瑞麟李强吕寒静魏为利张敏（同济）. 干细胞因子反义寡核苷酸对小鼠成纤维细胞-肥大细胞相互作用的影响[J]. 基础医学与临床, 2007, 27(7): 776-780.
[14]	卢宏达黄涛申雯竹甄燕孔庆志. 端锚酶和端粒酶反义寡核苷酸联合作用对人肺腺癌细胞A549端粒的影响[J]. 基础医学与临床, 2007, 27(12): 1314-1318.